Article info

Original research
Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade

Authors

  1. Correspondence to Dr Su-Hyung Park; park3{at}kaist.ac.kr; Dr Jaeho Jung; jaeho.jung{at}ablbio.com
View Full Text

Citation

Jeong S, Park E, Kim H, et al
Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade

Publication history

  • Accepted June 7, 2021
  • First published July 6, 2021.
Online issue publication 
November 02, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.